XBIO Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake The proposed transaction would create a Nasdaq-listed company focused on NET-targeting therapies, combining four clinical programs while transferring majority ownership to Santersus shareholders. Key Investor TakeawaysXenetic Biosciences (NASDAQ:XBIO) has signed a definitive share exchange agreement to acquire privately held Santersus AG in an all-stock transaction. | ||
 Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective blood purification platform. The all-stock deal hinges on shareholder approval and involves exchanging newly issued Xenetic shares for all outstanding Santersus equity. Following the transaction, the unified entity plans to rebrand as Santersus Bio, Inc. and trade on the Nasdaq Capital Market under the | ||